Serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 concentrations and prostate cancer risk: results from the European Prospective Investigation into Cancer and Nutrition.

TitleSerum insulin-like growth factor (IGF)-I and IGF-binding protein-3 concentrations and prostate cancer risk: results from the European Prospective Investigation into Cancer and Nutrition.
Publication TypeJournal Article
Year of Publication2007
AuthorsAllen, NE, Key, TJ, Appleby, PN, Travis, RC, Roddam, AW, Rinaldi, S, Egevad, L, Rohrmann, S, Linseisen, J, Pischon, T, Boeing, H, Johnsen, NFøns, Tjønneland, A, Grønbaek, H, Overvad, K, Kiemeney, L, H Bueno-de-Mesquita, B, Bingham, S, Khaw, KTee, Tumino, R, Berrino, F, Mattiello, A, Sacerdote, C, Palli, D, Quirós, JRamón, Ardanaz, E, Navarro, C, Larrañaga, N, González, C, Sánchez, M-J, Trichopoulou, A, Travezea, C, Trichopoulos, D, Jenab, M, Ferrari, P, Riboli, E, Kaaks, R
JournalCancer Epidemiol Biomarkers Prev
Volume16
Issue6
Pagination1121-7
Date Published2007 Jun
ISSN1055-9965
KeywordsAdult, Aged, Aged, 80 and over, Case-Control Studies, Enzyme-Linked Immunosorbent Assay, Humans, Insulin-Like Growth Factor Binding Protein 3, Insulin-Like Growth Factor I, Male, Middle Aged, Neoplasm Staging, Prostatic Neoplasms, Risk Factors
Abstract

BACKGROUND: Some studies suggest that elevated serum insulin-like growth factor (IGF)-I concentrations are associated with an increased risk of prostate cancer and, in particular, with an increased risk of advanced-stage prostate cancer.

METHODS: We analyzed the association between prediagnostic serum concentrations of IGF-I and IGF-binding protein-3 (IGFBP-3) and prostate cancer risk in a case-control study nested in the European Prospective Investigation into Cancer and Nutrition. This study includes 630 incident prostate cancer cases and 630 matched control subjects. Odds ratios and their 95% confidence intervals (95% CI) were calculated for prostate cancer risk associated with increasing IGF-I and IGFBP-3 concentrations using conditional logistic regression.

RESULTS: The risk of total prostate cancer in the highest versus the lowest third of serum peptide concentration was 1.35 (95% CI, 0.99-1.82; Ptrend = 0.08) for IGF-I, 1.39 (95% CI, 1.02-1.89; Ptrend = 0.12) for the IGF-I residuals after adjusting for IGFBP-3, 1.22 (95% CI, 0.92-1.64; Ptrend = 0.38) for IGFBP-3, and 1.01 (95% CI, 0.74-1.37; Ptrend = 0.75) for the IGFBP-3 residuals after adjusting for IGF-I. There was no significant difference in the association of peptide hormones and prostate cancer by stage of disease, although the association of serum IGF-I concentration with risk was slightly stronger for advanced-stage disease; the odds ratio for the highest versus the lowest third was 1.65 (95% CI, 0.88-3.08; Ptrend = 0.21) for IGF-I and 1.76 (95% CI, 0.92-3.40; Ptrend = 0.11) for IGF-I adjusted for IGFBP-3.

CONCLUSIONS: In this large nested case-control study, serum IGF-I concentration is not strongly associated with prostate cancer risk, although the results are compatible with a small increase in risk, particularly for advanced-stage disease; no association for IGFBP-3 was observed.

DOI10.1158/1055-9965.EPI-06-1062
Alternate JournalCancer Epidemiol. Biomarkers Prev.
Citation Key10.1158/1055-9965.EPI-06-1062
PubMed ID17548673
Grant ListG0401527 / / Medical Research Council / United Kingdom
U01 CA098216-01 / CA / NCI NIH HHS / United States
/ / Wellcome Trust / United Kingdom